GH Research PLC
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- GH Research PLC is a biotechnology company specializing in the discovery and development of novel antibiotics and anti-infective agents. The company focuses on producing a pipeline of small-molecule and biologic therapeutics aimed at addressing multidrug-resistant bacterial infections. GH Research’s main product offerings include innovative therapeutics targeting resistant pathogens such as Gram-positive and Gram-negative bacteria, with a portfolio that encompasses discovery, preclinical development, and early clinical stage compounds. The company operates primarily within the pharmaceutical and biotech industry segments, targeting hospitals, healthcare providers, and the global infectious disease treatment market. It was founded in 2013 and maintains its headquarters in London, United Kingdom. GH Research PLC also collaborates with various partners within the pharmaceutical industry to advance its drug candidates and expand its development capabilities. In the last 1-2 years, GH Research has undergone significant operational changes including the initiation of new clinical trials for its lead antibiotic candidates and expansion of its research pipeline through strategic collaborations and licensing agreements. The company has made advancements in its late-stage development programs, enhancing its position in the antimicrobial space. GH Research has also strengthened its financial base through capital raises to support ongoing clinical and development activities aimed at addressing the global health threat posed by antibiotic resistance. There are no recent name changes or rebranding reported. Overall, GH Research PLC combines proprietary drug discovery technologies with a focused development strategy in anti-infectives, maintaining a global operational footprint aimed at delivering next-generation antibiotic therapies to combat resistant bacterial infections.
GH Research Announces Publication of Phase 2a Postpartum Depression Results
GH Research: Rapid Onset And Short Action Change The Treatment Paradigm
These Analysts Revise Their Forecasts On GH Research After Q1 Results
GH Research Reports First Quarter 2026 Financial Results and Provides Business Update
GH Research Announces Pricing of $117.5 Million Underwritten Offering
FTSE 100 Live: London stocks slide as aerospace and defence sector falls
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness
Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On?
Psychedelics stocks rise after Trump order expands research, access pathways
Comparing Prenetics Global (NASDAQ:PRE) & GH Research (NASDAQ:GHRS)
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
GH Research FY25 Results: Strong Cash Position As GH001 Advances Toward Phase 3
GH Research Reports Full Year 2025 Financial Results and Provides Business Update
FDA Lifts Hold On GH Research's Depression Drug Trial After Two Years
GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026
Stock Market Today: S&P 500, Nasdaq Futures Rise, WTI Fluctuates Following US Strike On Venezuela— GH Research, Vertiv Holdings, Nukkleus In Focus
GH Research: GH001 Shows Robust Data Ahead Of FDA IND Decision
GH Research to Announce IND Status for GH001
Wall Street Analysts Think GH Research (GHRS) Could Surge 130.59%: Read This Before Placing a Bet
GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates